Abstract
Anti-inflammatory therapy has become the mainstay of chronic asthma therapy in children. Which medication should become the "first-line" choice of physicians depends on each medication's anti-inflammatory effectiveness, side effects, techniques required for administration, and ability to modify disease progression. Additionally, certain medications may be more effective than others for treating specific clinical conditions. Improved understanding of the inflammatory response in asthma suggests that none of the currently available medications are ideal and that new, less toxic, yet more effective therapies are needed to control inflammation.

This publication has 0 references indexed in Scilit: